Monopar Therapeutics Inc
MNPR41.650USD
+0.960+2.36%
시장 운영 시간 （ET）시세는 15분 지연됩니다
254.70M시가총액
손실P/E TTM
자세한 내용은 Monopar Therapeutics Inc 회사
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.
회사 정보
종목 코드 MNPR
회사 이름Monopar Therapeutics Inc
상장일Dec 19, 2019
CEODr. Chandler D. Robinson, M.D.
직원 수16
유형Ordinary Share
회계 연도 종료Dec 19
주소1000 Skokie Blvd Ste 350
도시WILMETTE
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호60091-1146
전화18473880349
웹사이트https://www.monopartx.com/
종목 코드 MNPR
상장일Dec 19, 2019
CEODr. Chandler D. Robinson, M.D.
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
73.47K
--
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
16.05K
--
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Kim R. Tsuchimoto
Ms. Kim R. Tsuchimoto
Director
Director
11.49K
--
Mr. Arthur J. Klausner
Mr. Arthur J. Klausner
Independent Director
Independent Director
6.17K
--
Mr. Raymond William (Bill) Anderson
Mr. Raymond William (Bill) Anderson
Independent Director
Independent Director
5.37K
--
Mr. Vu Quan
Mr. Vu Quan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
--
--
Dr. Patrice P. Rioux, M.D., Ph.D.
Dr. Patrice P. Rioux, M.D., Ph.D.
Acting Chief Medical Officer
Acting Chief Medical Officer
--
--
Mr. Andrew J. Cittadine
Mr. Andrew J. Cittadine
Chief Operating Officer
Chief Operating Officer
--
--
이름
이름/직위
직위
주식 보유
변동
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
73.47K
--
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
16.05K
--
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Kim R. Tsuchimoto
Ms. Kim R. Tsuchimoto
Director
Director
11.49K
--
Mr. Arthur J. Klausner
Mr. Arthur J. Klausner
Independent Director
Independent Director
6.17K
--
Mr. Raymond William (Bill) Anderson
Mr. Raymond William (Bill) Anderson
Independent Director
Independent Director
5.37K
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Sat, Jul 5
마지막 업데이트: Sat, Jul 5
주주
주주 유형
주주
주주
비율
Janus Henderson Investors
18.55%
Tactic Pharma LLC
13.45%
Gem Pharmaceuticals LLC
9.99%
Adage Capital Management, L.P.
9.80%
RA Capital Management, LP
8.36%
Other
39.85%
주주
주주
비율
Janus Henderson Investors
18.55%
Tactic Pharma LLC
13.45%
Gem Pharmaceuticals LLC
9.99%
Adage Capital Management, L.P.
9.80%
RA Capital Management, LP
8.36%
Other
39.85%
주주 유형
주주
비율
Corporation
29.77%
Investment Advisor/Hedge Fund
20.22%
Hedge Fund
16.45%
Venture Capital
8.36%
Individual Investor
4.79%
Investment Advisor
1.81%
Research Firm
0.55%
Pension Fund
0.15%
Other
17.91%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
75
5.02M
82.10%
-394.73K
2025Q1
72
5.03M
83.96%
+455.96K
2024Q4
54
4.84M
79.28%
+1.76M
2024Q3
40
1.90M
50.69%
+25.14K
2024Q2
43
1.96M
52.51%
+123.52K
2024Q1
46
1.91M
52.92%
+136.66K
2023Q4
44
1.88M
67.20%
+125.61K
2023Q3
42
1.87M
67.45%
+153.91K
2023Q2
38
1.84M
66.75%
+138.58K
2023Q1
38
1.70M
67.19%
-3.29K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Janus Henderson Investors
1.13M
18.55%
+87.51K
+8.36%
Mar 31, 2025
Tactic Pharma LLC
822.25K
13.45%
-33.33K
-3.90%
Apr 04, 2025
Gem Pharmaceuticals LLC
611.08K
9.99%
--
--
Apr 04, 2025
Adage Capital Management, L.P.
599.20K
9.8%
--
--
Mar 31, 2025
RA Capital Management, LP
511.21K
8.36%
--
--
Mar 31, 2025
AstraZeneca PLC
387.33K
6.33%
+387.33K
--
Oct 23, 2024
Point72 Asset Management, L.P.
168.16K
2.75%
+268.00
+0.16%
Mar 31, 2025
Adar1 Capital Management LLC
100.77K
1.65%
-29.26K
-22.50%
Mar 31, 2025
Hendricks (Diane)
93.75K
1.53%
--
--
Apr 04, 2025
Robinson (Chandler D)
73.47K
1.2%
+7.48K
+11.33%
Jun 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
iShares Micro-Cap ETF
0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
비율0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
비율0.02%
ProShares UltraPro Russell2000
비율0.01%
ProShares Hedge Replication ETF
비율0.01%
iShares Russell 2000 Growth ETF
비율0.01%
Global X Russell 2000 ETF
비율0.01%
Proshares Ultra Russell 2000
비율0.01%
iShares Russell 2000 ETF
비율0%
Avantis US Small Cap Equity ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
Aug 09, 2024
Merger
5<1
Aug 09, 2024
Merger
5<1
Aug 09, 2024
Merger
5<1
Aug 09, 2024
Merger
5<1
날짜
유형
비율
Aug 09, 2024
Merger
5<1
Aug 09, 2024
Merger
5<1
Aug 09, 2024
Merger
5<1
Aug 09, 2024
Merger
5<1
